Clinical Trial Update: Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating 25 mg and 50 mg doses of Proellex for recurrence of uterine fibroid symptoms has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Fibroids

Drugs mentioned

• Proellex (telapristone acetate)

Snippet

Sponsor: Repros Therapeutics Inc. | Conditions: Uterine Fibroids | Phase 3 | Status: WITHDRAWN